We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
MOVAPO POD (Stada Pharmaceuticals Australia Pty Ltd)
Product name
MOVAPO POD
Date registered
Evaluation commenced
Decision date
Approval time
143 (255 working days)
Active ingredients
apomorphine hydrochloride hemihydrate
Registration type
New generic medicine
Indication
MOVAPO POD is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. Conventional therapy should be continued during ‘on’ phases.